Skip to main content
. 2010 Jul 20;18(11):2028–2037. doi: 10.1038/mt.2010.148

Figure 2.

Figure 2

DC3-9dR-mediated silencing of SOCS-1 induces strong priming of Melan-A/MART-1-specific CD8+ T cell responses in vitro. (a,b) MDDCs from healthy HLA-A*0201+ donors were untreated or treated with SOCS-1 siRNA (complexed to DC3-9dR or lipofectamine), pulsed with Melan-A/MART-1 peptide (10 µg/ml) and cocultured with autologous CD8+ T cells for 7 days in the presence of IL-7 (20 U/ml) and IL-15 (5 U/ml). Representative flow cytometric analysis of Melan-A/MART-1 CD8+pentamer+ cells from one donor and (b) data from all five donors are shown. (c,d) Cognate T cells in a were restimulated with peptide-pulsed DCs and tested for cytokine production by (c) intracellular staining or by (d) Luminex assay. (e–g) Cultures from (a) were restimulated with Melan-A/MART-1 peptide-pulsed untreated- or SOCS1 siRNA-treated DCs, and after 7 days assayed for CD8+pentamer+ cell frequencies by (e) flow cytometry; representative data, (f) cumulative data from three donors, and (g) cytokine production by Luminex assay. DC, dendritic cell; IFN-γ, interferon-γ IL, interleukin; MDDC, myeloid-derived DC; siRNA, small interfering RNA; SOCS-1, suppressor of cytokine signaling-1.